SNIPR Biome
SNIPR Biome develops precision medicines for infections and diseases linked to antimicrobial resistance and microbiome dysbiosis, using CRISPR-based gene editing to selectively target pathogenic bacteria while sparing the rest of the microbial community. The company applies programmable CRISPR platforms, delivered by engineered phages or probiotics, to address difficult-to-treat infections and modulate the human microbiome. Its programs span discovery through Phase 2 clinical trials, with a significant patent portfolio supporting these innovations.
Industries
N/A
Patents
Products
A CRISPR-based oral therapeutic candidate designed to prevent bloodstream E. coli infections in patients with hematological cancers.
A CRISPR-based intravenous therapeutic candidate for uUTI/sepsis and kidney transplant patients targeting multidrug-resistant E. coli.
A gene therapy candidate using CRISPR to target specific pathogens linked to EED in vulnerable populations.
A program to target a prioritized panel of nine top antimicrobial resistant pathogens using rationally engineered CRISPR delivery solutions.
Precision medicine candidate delivering CRISPR payloads to eliminate Pseudomonas aeruginosa in the respiratory tract for chronic infection management.
A CRISPR-based oral therapeutic candidate designed to prevent bloodstream E. coli infections in patients with hematological cancers.
A CRISPR-based intravenous therapeutic candidate for uUTI/sepsis and kidney transplant patients targeting multidrug-resistant E. coli.
A gene therapy candidate using CRISPR to target specific pathogens linked to EED in vulnerable populations.
A program to target a prioritized panel of nine top antimicrobial resistant pathogens using rationally engineered CRISPR delivery solutions.
Precision medicine candidate delivering CRISPR payloads to eliminate Pseudomonas aeruginosa in the respiratory tract for chronic infection management.
Services
Provision of open research access to CRISPR gene editing patent portfolio for non-commercial academic or non-profit projects.
Guidance and opportunity for U.S.-licensed physicians to request investigational CRISPR-based therapeutics for eligible patients with serious, treatment-resistant E. coli infections.
Provision of open research access to CRISPR gene editing patent portfolio for non-commercial academic or non-profit projects.
Guidance and opportunity for U.S.-licensed physicians to request investigational CRISPR-based therapeutics for eligible patients with serious, treatment-resistant E. coli infections.
Expertise Areas
- CRISPR gene editing
- Precision microbiome engineering
- Antimicrobial resistance solutions
- Therapeutic protein and peptide delivery
Key Technologies
- CRISPR/Cas gene editing
- Bacteriophage delivery systems
- Engineered probiotic delivery
- Programmable DNA-guided vectors
News & Updates
Raised significant growth capital to expand clinical pipeline and accelerate development of antimicrobial resistance (AMR)-targeted CRISPR therapeutics.
Received funding to support the advancement of CRISPR-based bacteriophage medicine into clinical trials.
Financing to develop new antimicrobials for situations where current antibiotics are ineffective.
Demonstrated compassionate use of CRISPR therapy in a patient with rare multidrug-resistant E. coli infection.
Patent portfolio for CRISPR-based gene engineering of prokaryotes made freely available for non-profit/academic research.
Patent covers use of a novel CRISPR-Cas system in prokaryotic and eukaryotic cells, expanding the platform's reach.
Raised significant growth capital to expand clinical pipeline and accelerate development of antimicrobial resistance (AMR)-targeted CRISPR therapeutics.
Received funding to support the advancement of CRISPR-based bacteriophage medicine into clinical trials.
Financing to develop new antimicrobials for situations where current antibiotics are ineffective.
Demonstrated compassionate use of CRISPR therapy in a patient with rare multidrug-resistant E. coli infection.
Patent portfolio for CRISPR-based gene engineering of prokaryotes made freely available for non-profit/academic research.
Patent covers use of a novel CRISPR-Cas system in prokaryotic and eukaryotic cells, expanding the platform's reach.